Premium
Hemostatic Properties of Topically Applied Q8009 a Snake Venom Protease
Author(s) -
Warner Roscoe L,
McClintock Shan D,
Barron Adam G
Publication year - 2006
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.20.4.a653-b
Subject(s) - hemostasis , thrombin , chemistry , in vivo , venom , anesthesia , medicine , surgery , biology , platelet , biochemistry , microbiology and biotechnology
Previous in vitro work characterized the protease Q8009 from the venom of the Australian brown snake Pseudonaja textilis textilis with hemostatic properties and Factor Xa‐like activity. In vivo studies reported herein indicate that Q8009 mixed with collagen matrix and applied to surgical injury sites is superior to thrombin in blood loss reduction and a shorter time‐to‐hemostasis. The dermal injury model involved a dermal incision (1 mm deep x 5 mm in length) on each hind limb manus between digits 2 and 3. The tail‐tip model utilized transection of the last 2 mm of the tail‐tip. Blood was collected for 12 one‐minute intervals or until hemostasis, and blood loss was measured by quantifying hematin concentration. In the dermal injury model, Q8009 at concentrations of 100 [mu]g/mL, 250 [mu]g/mL and 1,000 [mu]g/mL significantly reduced (p<0.001) blood loss, compared to thrombin and reduced the time‐to‐hemostasis to ~ 2.0 minutes compared to 4.77 minutes with thrombin. In the tail‐tip transection model, Q8009 and collagen matrix did not significantly reduce blood loss relative to thrombin. However, Q8009 (1,000 [mu]g/mL) without collagen matrix, significantly reduced (p<0.001) blood loss from the tail wound. When the Tail‐Tip and Dermal models were averaged together, thrombin reduced overall blood loss by 72%, Q8009 at 100 [mu]g/mL, 250 [mu]g/mL and 1,000 [mu]g/mL reduced blood loss by 75%, 90% and 83%, respectively. Therefore, topical application of Q8009 significantly reduced total blood loss and shortened the time‐to‐hemostasis, when compared to thrombin. This work was supported by QRxPharma.